Biosyngens, CAR-T

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Veröffentlicht: 07.08.2025 um 18:08 Uhr, prnewswire.co.uk

Biosyngen Spain New York China Austria United Kingdom California

View original content:https://www.prnewswire.co.uk/news-releases/biosyngens-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii-trial-phase-i-trial-data-debut-at-esmo-2024-annual-congress-302251738.html

en | boerse | 67931471 |